SCHEMBL18539740

SCHEMBL18539740

CCOCc1nc(-c2ccccc2)ncc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
RAB9A P51151 4/20 0.48
MAPT P10636 3/20 0.48
NPC1 O15118 3/20 0.48
TP53 P04637 2/20 0.48
LMNA P02545 3/20 0.43
MAPK1 P28482 2/20 0.43
ATM Q13315 1/20 0.43
KMT2A Q03164 1/20 0.41
CYP1A2 P05177 2/20 0.40
POLB P06746 2/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CSNK1D P48730 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18549308 0.82 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL18539734 0.79 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL18549710 0.79 MAPT (0.35) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL18539735 0.79 MAPT (0.36) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL18539732 0.76 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL27517945 0.73 PDE4B (0.47) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL18539736 0.71 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL6409483 0.71 L3MBTL1 (0.50) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL27946093 0.71 SMN1; SMN2 (0.39) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL31437277 0.70 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170050934-A1 ETHERIC (ETHEREAL) OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR ITS PRODUCTION ASAHI GLASS COMPANY, LIMITED (JP) 2017-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050934-A1 ETHERIC (ETHEREAL) OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR ITS PRODUCTION CYP2B6, PFAS, CYP2F1 ALDH1A1 1430/4885SMN1; SMN2 4379/4885RAB9A 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.